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Objectives: In 2017, AMP, ASCO and CAP jointly published the ﬁrst formalized classiﬁcation system for the interpretation and reporting of sequence variants in cancer. The challenges of incorporating new variant interpretation guidelines into existing, validated workﬂows have likely
hampered adoption and implementation in labs with classiﬁcation methods in place. Ambiguity in
assigning clinical signiﬁcance across guidelines is grounded in differential weighting of evidence
used in variant assessment. Therefore, we undertook an internal process-improvement exercise to
correlate the two classiﬁcation schemes using historical laboratory data.
Design and methods: Existing clinical variant assignments from 40 consecutive oncology cases
comprising 150 somatic variants were re-assessed according to the 2017 AMP/ASCO/CAP scheme.
Approximately 50% of these were cancers of the gynecologic tract.
Results: Our laboratory-developed (GPS) classiﬁcations for ‘actionable’ variants and variants of
uncertain clinical signiﬁcance mapped consistently with the AMP/ASCO/CAP Tiers I-III. The
majority of Level 1 variants were reclassiﬁed to Tier I (21/25; 84%) while all Level 2 and Level 4
variants were assigned to Tier II (9/9; 100%) and Tier III (17/17; 100%), respectively. The
greatest variability was seen for GPS Level 3 variants, which was strongly inﬂuenced by TP53
interpretations. Ultimately, we found that most GPS Level 3 variants were classiﬁed as Tier III (77/
99; 77.8%).
Conclusions: Our internally developed 5-level classiﬁcations mapped consistently with the proposed AMP/ASCO/CAP 4-Tiered system. As a result of this analysis, we can provide a framework
for other labs considering a similar transition to the 2017 AMP/ASCO/CAP guidelines and a
rationale for explaining speciﬁc discrepancies.

1. Introduction
In 2011, the Genomics and Pathology Services (GPS) clinical laboratory at Washington University School of Medicine implemented
guidelines for the interpretation and reporting of sequence variants identiﬁed through clinical next-generation sequencing (NGS)
analysis. The NGS assays offered by GPS include tumor mutational proﬁling, diagnostic testing for disorders of somatic mosaicism, and
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whole exome-based gene panels for diagnosis of cardiac and renal diseases, and immunodeﬁciency (congenital neutropenia) with a
suspected genetic component. In practice, multiple lines of evidence are evaluated in order to determine the reported clinical classiﬁcations. These sources, reviewed in Ref. [1], include, but are not limited to allelic fraction within population databases (e.g., ExAC,
gnomAD), literature review (e.g., OMIM, ClinVar, PubMed), and in silico prediction tools based on evolutionary conservation and
tertiary protein domain structure (e.g., PolyPhen, SIFT, GERPþþ). For oncology, additional variant level analyses utilize speciﬁc databases, including COSMIC, cBioPortal, and CIViC.
In combination with guidelines and recommendations from professional organizations (e.g. NCCN), our clinical NGS laboratory
developed a strategy to classify somatic variants identiﬁed in tumor-only mutational proﬁling for patients with cancer [2]. The overall
goal of the classiﬁcation scheme was to highlight the most important and thus ‘actionable’ variants to the oncologist. As a result, ﬁve
levels were chosen for stratiﬁcation and are brieﬂy described here. Level 1 are those variants deemed to be of diagnostic, prognostic,
and/or therapeutic value in the cancer type of the patient. Level 2 is reserved for variants similar in scope to Level 1 but apply to a
cancer type distinct from the one the patient presents with. This distinction allows the treating physician to evaluate interventions,
including off-label drug usage that may prove to be relevant. Level 3 refers to variants that have been previously reported in cancer or
another genetic disease, but without compelling evidence to predict its clinical signiﬁcance or relevance to the patient’s disease. Level 4
denotes variants of uncertain clinical signiﬁcance, which includes novel (previously unreported) variants and variants for which there is
insufﬁcient evidence to support a pathogenic contribution. Finally, Level 5 refers to well-documented polymorphisms occurring at a
frequency greater than 1.0% within any population or subpopulation.
It was not until 2017, that AMP, ASCO and CAP jointly published the ﬁrst formalized a clinical classiﬁcation system for the interpretation and reporting of sequence variants in cancer [1]. This classiﬁcation scheme was predicated on a 4-Tiered system, with signiﬁcant weight placed upon published evidence for making stratiﬁcation decisions. These current recommendations are brieﬂy
summarized here and compared with our current GPS-developed classiﬁcation system. Tier I includes variants of strong clinical signiﬁcance based upon therapeutic, prognostic and diagnostic criteria. Two distinct levels of evidence provide support for this classiﬁcation: Level A identiﬁes FDA-approved disease-speciﬁc therapies as well as professional guidelines whereas Level B is reserved for
well-powered studies with expert consensus that have not yet entered professional recommendations. As such, the AMP/ASCO/CAP
Tier I and the GPS Level 1 are well aligned. As a general theme, while our established GPS classiﬁcation assignments are not based upon
a formal structure for the strength of the evidence levels, scientiﬁc rigor is considered in determining the actionable nature of the variant
under evaluation. Tier II classiﬁes variants similar to Tier I, with the allowance that levels of evidence are less stringent. Thus, this tier
describes variants of potential clinical signiﬁcance in terms of their diagnostic, therapeutic and prognostic attributes. For example,
evidence Level C includes off-label use of FDA-approved therapies and multiple small studies, whereas Level D is reserved for those
variants for which there is only preclinical data or case reports. Tier III refers to variants of uncertain clinical signiﬁcance (VUS), which
maps directly to the GPS Level 4; the AMP/ASCO/CAP Tier IV describes benign or likely benign variants, corresponding to GPS Level 5.
The challenges of adopting new guidelines in variant interpretation are multi-fold and are likely encountered by labs like ours that
have implemented classiﬁcation schemes prior to the publication of the 2017 guidelines. Primarily, it is unclear if one can easily
correlate the new classiﬁcation hierarchy to the current one, especially with Tiers I and II (Fig. 1A). The difﬁculty in mapping

Fig. 1. (A) Predicted and (B) observed transition of current (GPS) classiﬁcation of variants to the 2017 guidelines proposed by AMP/ASCO/
CAP. (A) Gradient colors (for Level 2 and Level 3) represent the uncertainty of re-assignment based upon differences in the classiﬁcation criteria. (B)
The differences in mapping variants compared to panel A reﬂect the data collected as described within the text. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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assignments across guidelines stems from differential weighting of criteria used to inform the process. Secondly, comparing historical
results with contemporary ones may prove difﬁcult for longitudinal quality assessment and process improvement activities. Lastly, a
certain degree of subjectivity in variant assessment among clinical variant scientists precludes the development of a linear, and thus
automated, transition between classiﬁcation guidelines. With these challenges in mind, we developed a method to correlate the two
classiﬁcation schemes using historical de-identiﬁed variant data.
2. Methods
We speciﬁcally developed the following approach to better gauge the impact of replacing classiﬁcation methods from our current,
established GPS scheme to the 2017 AMP/ASCO/CAP guidelines. A series of 150 somatic variants previously assigned to the top 4 GPS
levels (Level 1, 2, 3 and 4) identiﬁed in 40 solid tumor and hematologic cancer cases were selected for a retrospective analysis. Inclusion
criteria for this study is that all variants were identiﬁed from consecutive cases over a 6-month period (June through Dec 2017). This
was performed by a single qualiﬁed pathologist and ultimately reviewed by a team of clinical variant scientists including three experienced pathologists at Washington University formally trained in clinical variant interpretation. Prior interpretive information available at the time of clinical reporting along with further evaluation of the clinical case allowed these variants to be scored according to the
2017 AMP/ASCO/CAP guidelines. The variants in this report were classiﬁed with the evidence available in May 2019. In our subset of
data, evidence at that time did not change the classiﬁcations previously applied to the GPS system. The institutional review board of
Washington University School of Medicine deemed this study as not ﬁtting the deﬁnition of human subjects research; thus, no IRB
protocol was required.
3. Results and discussion
Variants for the mapping exercise were selected from previously reported oncology cases involving the following cancer types: cervix
(10), ovarian (6), endometrial (4), hematopoietic/myeloid (4), thyroid (2), gastrointestinal tract (2), head and neck (2), unknown
primary (2), and one case each representing lung, breast, pancreas, sarcoma, as well as a rhabdoid tumor and a ﬁbroma. Of note, these
cases were skewed toward cancers of the gynecologic tract (50%) and so the variants under investigation would potentially be overrepresented by those prevalent in these tumors. Across this group of tumors, GPS-reported variants included 25 at Level 1, 9 at Level 2,
99 at Level 3, and 17 at Level 4. Noticeably, the most common variant classiﬁcation reported was Level 3. As suggested above, this level
represents the greatest variability in correlating variant assignment to the 2017 guidelines, allowing us to provide a meaningful

Fig. 2. Reassignments of variants by level. Data represent the 40 tumor types and 150 total variants assessed. The percent of variants reclassiﬁed
into the respective Tier is shown with actual values above the individual measurements in the bar graph. GPS classiﬁcation levels shown for each
graph are as described in Fig. 1. *2 Level 1 to II-C variants were in PIK3CA in cervical cancer (see text). **17 of 21 Level 3 to II-C variants were in
TP53 (see text).
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comparison.
Focusing initially on Level 1 (Fig. 2A), we found that a majority of variants were reclassiﬁed as Tier I-A or Tier I–B (21/25; 84%)
based on the clinical presentation and existing published evidence. Most of these were Tier I–B, representing the stricter criteria of
evidence required to support a level Tier I-A classiﬁcation. Of the 4 variants identiﬁed as Tier II-C, arising largely from a lack of evidence
to support a higher classiﬁcation, 2 were PIK3CA variants. As of May 2019, the FDA approved therapies for HER2-negative, ER/PRpositive breast carcinoma include alpelisib, a PI3Kα inhibitor for use in patients with PIK3CA mutations [3]. Off-label FDA use for
other tumor types clearly placed these variants in Tier II-C, although prior interpretations of these variants as prognostic for certain
tumor types placed them into the GPS Level 1. Such discrepancies are rare, but point out limitations in transitioning variant level assignments. Our 9 GPS Level 2-assigned variants (Fig. 2B) as all mapped to AMP/ASCO/CAP Tier II, with all but one given an evidence
level of C.
The greatest variability, as predicted, was observed for our diverse GPS Level 3 variants (Fig. 2C). A majority (60/99; 60.6%) of these
were classiﬁed as AMP/ASCO/CAP Tier III (VUS). This highlights the utility of the AMP/ASCO/CAP guidelines, since many GPS Level 3
variants are thus classiﬁed based upon inclusion in publicly-accessible variant databases, where detailed annotations are often lacking.
In other words, that a variant has been previously identiﬁed does not mean it has escaped the VUS classiﬁcation. The onus then resides
on the clinical variant scientist to report potentially interesting or actionable VUS, with the consequence that these variants will not
come to the immediate attention of oncologists using laboratories that do not report or provide interpretations for these VUS. Thus,
adoption the 2017 guidelines has the potential to decrease uncertainty and improve clarity the ﬁnal clinical report, but with the potential cost of ineffective communication of VUS that may nonetheless have important implications for a particular case (e.g., a patient
for whom clinical trial eligibility criteria include unspeciﬁed variants identiﬁed in speciﬁc genes).
Interestingly, 17 of 21 (81%) GPS Level 3 variants mapped to AMP/ASCO/CAP Tier II-C were variants in TP53. There is a conﬂicting
body of literature on the actionability of TP53 variants, based largely upon the type of cancer under review and not limited to a speciﬁc
variant. For example, TP53 can be a biomarker of poor therapeutic response in AML [4] but not in other cancer types. Additionally,
therapeutic approaches have been proposed to inhibit dominant-negative functions of mutant p53 or rescue p53 loss of function in a
variety of tumor types. In breast cancer, TP53 mutations have been used as a marker of responsiveness to depirubicin-cyclophosphamide
[5]. In non-small cell lung cancer, TP53 has been used as a marker of responsiveness to carboplatin/gemcitabine [6]. In
chemotherapy-refractory metastatic colorectal carcinoma patients treated with cetuximab, TP53 is a predictor of better clinical outcomes [7]. Finally, there are ongoing clinical trials targeting either wild type or mutant TP53 suggesting use as positive and negative
selection strategy (i.e. inclusion or exclusion criteria). However, factoring in the weight of the evidence and lack of preclinical trials, a
conservative interpretation places these variants more appropriately into Tier III, thus increasing the number of Level 3 variants
reclassiﬁed as Tier III at 77.8% (77/99). Finally, all 17 Level 4 variants were correctly assigned to Tier III as variants of unknown clinical
signiﬁcance (Fig. 2D). While we did not explicitly interrogate variants at Level 5, a preliminary mapping indicates that all would map
directly into the AMP/ASCO/CAP Tier IV, as expected. In the absence of paired normal tissue for comparison, these include
well-documented polymorphisms occurring at a population frequency greater than 1.0%. However, we have recently shown that even
this cutoff may be too high [8]. A summary of these reclassiﬁcation efforts is provided in Fig. 1B.
Our analysis presented here demonstrated that a transition to the 2017 AMP/ASCO/CAP guidelines is likely to correlate well with
current evidence-based classiﬁcation systems. Although similar sources of evidence were used to guide clinical interpretations, the
strength of the evidence affected the AMP/ASCO/CAP variant assignment to a greater degree. A standardized approach to evaluating the
literature with discretely deﬁned literature sources could reduce the observed variability. As such, we anticipate adoption of the AMP/
ASCO/CAP guidelines in parallel with an ongoing somatic variant assessment quality assurance program. Ultimately, the development
and utilization of a standardized approach to evaluating the literature with discretely deﬁned literature sources could reduce the
observed variability and effectively increase adoption of the AMP/ASCO/CAP guidelines. The standards should be harmonized with
those for curation of variant-related data in emerging cancer knowledgebases. Alignment of clinical laboratory and oncology physicians
about the utility of these consensus guidelines will also be critical for their ultimate adoption.
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